Silence Therapeutics (SLN) Return on Equity (2023 - 2026)

Silence Therapeutics' Return on Equity history runs 4 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Equity fell 1.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (down 1.0% YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
• Return on Equity came in at 0.01% for Q1 2026 at Silence Therapeutics, down from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q2 2024 to a low of 0.03% in Q3 2023.
• A 4-year average of 0.01% and a median of 0.01% in 2025 frame the typical range for Return on Equity.
• Across the five-year window, Return on Equity increased 2 bps in 2024 and retreated 1 bps in 2025, its largest moves.
• Silence Therapeutics' Return on Equity stood at 0.03% in 2023, then jumped by 85 bps to 0.0% in 2024, then plunged by 235 bps to 0.01% in 2025, then retreated by 4 bps to 0.01% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.01%, 0.01%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison